Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9313924 | 0.81 | LMNA (0.41) | TP53MAPT | |
| SCHEMBL16359872 | 0.79 | MMP1 (0.31) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL13624500 | 0.79 | MMP1 (0.38) | TP53MMP1MMP2MMP3MMP9 | |
| SCHEMBL44463 | 0.78 | TP53 (0.50) | TP53MMP1MMP2MMP3MMP9 | |
| SCHEMBL21768461 | 0.78 | TP53 (0.50) | TP53MMP1MMP2MMP3MMP9 | |
| SCHEMBL23673200 | 0.78 | TP53 (0.50) | TP53MMP1MMP2MMP3MMP9 | |
| SCHEMBL8557040 | 0.78 | TP53 (0.50) | TP53MMP1MMP2MMP3MMP9 | |
| SCHEMBL18651139 | 0.78 | TP53 (0.50) | TP53MMP1MMP2MMP3MMP9 | |
| SCHEMBL12046593 | 0.78 | TP53 (0.50) | TP53MMP1MMP2MMP3MMP9 | |
| SCHEMBL29743149 | 0.78 | TP53 (0.50) | TP53MMP1MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8956644-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2015-02-17 | — | — | US | claimed |
| US-20130317456-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2013-11-28 | — | — | US | claimed |
| US-20130273139-A1 | TRANSDERMAL DELIVERY SYSTEMS | DURECT CORPORATION | 2013-10-17 | — | — | US | claimed |
| EP-2484347-A1 | Transdermal delivery systems comprising bupivacaine | Durect Corporation (US) | 2012-08-08 | — | — | EP | claimed |
| EP-2117521-B1 | TRANSDERMAL DELIVERY SYSTEMS COMPRISING BUPIVACAINE | DURECT CORP (US) | 2012-06-27 | — | — | EP | claimed |
| US-20090060986-A1 | Transdermal delivery systems | DURECT CORPORATION | 2009-03-05 | — | — | US | claimed |
| WO-2008066642-A2 | TRANSDERMAL DELIVERY SYSTEMS COMPRISING BUPIVACAINE | DURECT CORPORATION (US) | 2008-06-05 | — | — | WO | claimed |
| US-20180110739-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170007549-A1 | Transdermal Delivery Systems | DURECT CORPORATION | 2017-01-12 | — | — | US | disclosed |
| US-8956644-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130317456-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130273139-A1 | TRANSDERMAL DELIVERY SYSTEMS | DURECT CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-8337883-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2484347-A1 | Transdermal delivery systems comprising bupivacaine | Durect Corporation (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2117521-B1 | TRANSDERMAL DELIVERY SYSTEMS COMPRISING BUPIVACAINE | DURECT CORP (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20090060986-A1 | Transdermal delivery systems | DURECT CORPORATION | 2009-03-05 | — | — | US | disclosed |
| WO-2008066642-A2 | TRANSDERMAL DELIVERY SYSTEMS COMPRISING BUPIVACAINE | DURECT CORPORATION (US) | 2008-06-05 | — | — | WO | disclosed |